Neoadjuvant therapy is an essential part of high-risk stage III resectable melanoma management, with combination ...

Neoadjuvant platinum-based chemotherapy improves structure preservation (SP) for patients with T3, T4a, and selected T4b ...

Neoadjuvant chemotherapy prior to surgery and postoperative radiation therapy could improve organ preservation in patients ...

For patients with early-stage triple-negative breast cancer, neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant ...

While neoadjuvant therapy in stage III or great melanoma is already the standard of care, new research presented at ESMO ...

Researchers investigated the efficacy of total neoadjuvant treatment followed by nonoperative management in patients with locally advanced rectal cancer.

In KEYNOTE-522, treatment with neoadjuvant pembrolizumab and chemotherapy, followed by adjuvant pembrolizumab, led to ...

Imfinzi and chemotherapy before surgery, followed by Imfinzi after surgery, generated survival benefits in cisplatin-eligible ...

Notably, patients benefited from pembrolizumab regardless of whether they achieved a pathologic complete response (pCR), ...

Results from triple combination of efti, radiotherapy and KEYTRUDA® (pembrolizumab) to be presented at the Connective Tissue Oncology Society ...

(UroToday.com) The 2024 IBCN annual meeting included a session on molecular subtyping in the 2024, featuring a presentation by Dr. Saum Ghodoussipour discussing the LUMBER-NAC trial in progress. A ...

In 2021, the FDA blasted Merck for using a premature endpoint to pursue a Keytruda approval in early-stage triple-negative ...